- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06326047
Een onderzoeksstudie waarin wordt vergeleken hoe goed verschillende doses van het medicijn NN0519-0130 de bloedsuikerspiegel verlagen bij mensen met diabetes type 2
Onderzoek naar de veiligheid en werkzaamheid van eenmaal per week NNC0519-0130 bij deelnemers met diabetes type 2 – een dosisonderzoek
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Campbelltown, New South Wales, Australië, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Australië, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Australië, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australië, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Australië, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Australië, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Australië, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Australië, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australië, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Australië, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Australië, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Australië, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Australië, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Australië, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Australië, 6160
- Fremantle Hospital
-
-
-
-
-
Québec, Canada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Canada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Canada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Canada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Canada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Canada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Canada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Canada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Canada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Canada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Canada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Canada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
-
Bengaluru, Indië, 560054
- MS Ramaiah
-
New Delhi, Indië, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Indië, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Indië, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Indië, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Indië, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Indië, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Indië, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Indië, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Indië, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japan, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japan, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
California
-
Chula Vista, California, Verenigde Staten, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Verenigde Staten, 93720
- Valley Research
-
Inglewood, California, Verenigde Staten, 90301
- 310 Clinical Research
-
La Mesa, California, Verenigde Staten, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Verenigde Staten, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Verenigde Staten, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Verenigde Staten, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Verenigde Staten, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Verenigde Staten, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Verenigde Staten, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Verenigde Staten, 91602
- Med Partners, Inc.
-
Torrance, California, Verenigde Staten, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Verenigde Staten, 92780
- University Clin Investigators
-
Walnut Creek, California, Verenigde Staten, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Verenigde Staten, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Verenigde Staten, 33756
- Innovative Research of W FL
-
Miami, Florida, Verenigde Staten, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Verenigde Staten, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Verenigde Staten, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Verenigde Staten, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Verenigde Staten, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Verenigde Staten, 20745
- MD Medical Research
-
Rockville, Maryland, Verenigde Staten, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Verenigde Staten, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Verenigde Staten, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Verenigde Staten, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Verenigde Staten, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Verenigde Staten, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Verenigde Staten, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Verenigde Staten, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Verenigde Staten, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Verenigde Staten, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Verenigde Staten, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Verenigde Staten, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Verenigde Staten, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Verenigde Staten, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Verenigde Staten, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Verenigde Staten, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Verenigde Staten, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Verenigde Staten, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Verenigde Staten, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Verenigde Staten, 75230
- Zenos Clinical research
-
Forney, Texas, Verenigde Staten, 75126
- Care United Research, LLC
-
Houston, Texas, Verenigde Staten, 77004
- Endocrine Associates Houston
-
Houston, Texas, Verenigde Staten, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Verenigde Staten, 75039
- Tekton Research
-
Lewisville, Texas, Verenigde Staten, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Verenigde Staten, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Verenigde Staten, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Verenigde Staten, 23606
- TPMG Clinical Research
-
-
-
-
-
Seoul, Zuid -Korea, 05505
- Asan Medical Center
-
Seoul, Zuid -Korea, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Zuid -Korea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Zuid -Korea, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Zuid -Korea, 13620
- Seoul National University Bundang Hospital
-
-
-
-
Free State
-
Bloemfontein, Free State, Zuid-Afrika, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Zuid-Afrika, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Zuid-Afrika, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Zuid-Afrika, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Zuid-Afrika, 4170
- Dr T Padayachee
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-vergelijker: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimenteel: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-vergelijker: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimenteel: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-vergelijker: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimenteel: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-vergelijker: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimenteel: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-vergelijker: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Actieve vergelijker: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Tijdsspanne: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Tijdsspanne: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Tijdsspanne: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Tijdsspanne: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NN9541-4945
- U1111-1291-9196 (Andere identificatie: World Health Organization (WHO))
- jRCT2031230704 (Register-ID: JRCT)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .